Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557404 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938782 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL3717223 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938791 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL17782306 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL24528974 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL1764741 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL19156 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL17548234 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL29347914 | 0.80 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240028-B1 | Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical | INTRA CELLULAR THERAPIES INC (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| CN-101969774-A | Organic compounds | INTRA CELLULAR THERAPIES INC | 2011-02-09 | — | — | CN | disclosed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| EP-2240028-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009073210-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273753-A1 | ORGANIC COMPOUNDS | OPRD1, PGR, HTR1D | MEN1 4649/4885CYP2D6 215/4885CYP2C19 128/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | MEN1 4689/4885CYP2D6 235/4885CYP2C19 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.